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Correspondence
To the Editor: Plasmacytoid dendritic cells (pDCs) represent a subset of dendritic cells. There are two distinct forms of neoplasms derived from pDCs; the one is blastic plasmacytoid dendritic cell neoplasm (BPDCN) and the other is mature pDCs proliferation coexisted with myeloid tumors. The mature pDCs in myeloid tumor are characterized by a lineage-negative human leukocyte antigen (HLA) It is unambiguous that the diagnosis of the patient is AML transferred from PMF coexisted with MGUS. What is the reason of pDCs proliferation in the BM? Is it BPDCN or mature pDCs proliferation coexisted with myeloid tumor? A highly suspected diagnosis of BPDCN can be made when skin lesions exist, four antigens among CD4, CD56, CD123, TCL1, and CD303 are expressed by neoplastic cells and myeloid/lymphoid system specific markers such as CD117, MPO, CD20, and CD3 are negative. [1] This patient did not have skin lesions and the immunophenotypic characteristic of BPDCN. Mature pDCs proliferation coexisted with myeloid tumors is rare and affects predominantly male individuals (75%) with a median age of 69 years. Prognosis is usually poor, that is mainly due to the evolution of the myeloid neoplasm rather than expansion of pDCs. These mature pDCs show largely the same immunoprofile as their reactive counterparts, CD123, BDCA2, and TCL1 positive, but occasionally aberrantly express CD2, CD5, CD7, CD10, CD13, CD14, CD15, and CD33. CD56 is usually negative. Several cases with positive CD56 are summed in Supplementary Table 1 . [2, 3] We suspect that the advanced age and giving up chemotherapy may contribute to the poor prognosis of the patient reported here. The expression of CD56 suggests that the pDCs in these patients might be derived from monoblast cells.
Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website.
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The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understand that his name and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. [2] 24/male CMML + + + + LN, SK --8 (DOD) 2 [2] 50/male AML-M4 + + + + LN, SK, BM --11 (AWD) 3 [2] 63/female U-CMP + + --LN, BM --15 (DOD) 4 [2] 80/male U-MDS/MP + + + + LN, BM --43 (DOD) 5 [2] 62/female AML-M5 + ---LN, BM --15 (DOD) 6 [2] 52/male CMML + + --LN, BM --13 (AWD) 7 [3] 56/male AML transferred from CD56 
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